Stifel Nicolaus Has Lowered Expectations for Affimed (NASDAQ:AFMD) Stock Price

Affimed (NASDAQ:AFMD) had its price objective reduced by Stifel Nicolaus from $5.00 to $4.00 in a report released on Friday,Benzinga reports. They currently have a hold rating on the biopharmaceutical company’s stock.

Other analysts have also issued reports about the company. HC Wainwright restated a “buy” rating and issued a $10.00 price target on shares of Affimed in a report on Friday. Cantor Fitzgerald restated an “overweight” rating on shares of Affimed in a report on Monday, September 9th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and four have issued a buy rating to the company’s stock. According to MarketBeat.com, Affimed presently has a consensus rating of “Moderate Buy” and an average target price of $16.00.

Affimed Price Performance

Shares of Affimed stock opened at $3.16 on Friday. The company has a quick ratio of 2.71, a current ratio of 2.71 and a debt-to-equity ratio of 0.13. Affimed has a 12 month low of $2.92 and a 12 month high of $8.95. The business has a fifty day simple moving average of $3.49 and a 200 day simple moving average of $4.51.

Affimed (NASDAQ:AFMD) last announced its quarterly earnings data on Thursday, September 5th. The biopharmaceutical company reported ($1.09) EPS for the quarter, missing analysts’ consensus estimates of ($1.00) by ($0.09). Affimed had a negative return on equity of 165.35% and a negative net margin of 7,836.26%. The company had revenue of $0.17 million for the quarter, compared to analyst estimates of $1.67 million. Sell-side analysts predict that Affimed will post -4.25 EPS for the current fiscal year.

Institutional Trading of Affimed

A number of institutional investors have recently modified their holdings of AFMD. FMR LLC raised its holdings in Affimed by 30.0% during the third quarter. FMR LLC now owns 17,696 shares of the biopharmaceutical company’s stock worth $59,000 after acquiring an additional 4,086 shares in the last quarter. Choreo LLC bought a new stake in Affimed during the second quarter worth about $54,000. Intellectus Partners LLC raised its holdings in Affimed by 12.2% during the third quarter. Intellectus Partners LLC now owns 94,361 shares of the biopharmaceutical company’s stock worth $317,000 after acquiring an additional 10,250 shares in the last quarter. Jane Street Group LLC bought a new stake in Affimed during the third quarter worth about $44,000. Finally, Point72 Asset Management L.P. increased its position in Affimed by 4.6% during the third quarter. Point72 Asset Management L.P. now owns 342,856 shares of the biopharmaceutical company’s stock worth $1,152,000 after buying an additional 15,108 shares during the last quarter. 30.82% of the stock is currently owned by institutional investors.

About Affimed

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany. The company’s lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase Ib clinical trial for hodgkin lymphoma, and completed Phase IIb clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development for the treatment acute myeloid.